Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: leo_74 who wrote (13634)	9/22/2004 12:56:06 AM
From: SofaSpud	Respond to of 14101

A couple of thoughts. The new board has a huge task ahead of it -- you can't turn a situation like this around with nice thoughts and good intentions. They need cash. They need cash flow. And bloody soon. The thing that made me capitulate and sell was when Pensaid sales effectively stopped growing after two quarters. Ya, they were double y/y. But this last quarter wasn't materially different from the two before it. So what's up? Since it's not approved for long-term use, do you get one scrip with maybe two refills and that's it? If that's the case, then Pennsaid isn't going to save the company, no matter who is running it. Let me be clear -- I don't know if that's what's going on -- but I do know there hasn't been meaningful growth for a while. The real short-term thing I'm afraid of is like what happens in politics when a government is defeated. Invariably the new guys come in and say 'the books are worse than we were led to believe.' If that happens with DMX, then there's yet another buying opportunity coming up. Just a couple of random thoughts. As I said, I don't have a position at the moment, although I've lost lots of money here in the past.

To: leo_74 who wrote (13634)	9/22/2004 3:53:45 AM
From: axial	Respond to of 14101

Hi, leo - It's good to see the thread returning to life. "How does everyone view what has happened today and will it effect Dimethaid / share price in the future?" The patient is in rough shape. 1 - FIRST AID & INTENSIVE CARE - Treat the obvious wounds. Patient will need an immediate cash transfusion. Treat for shock. Restore calm. Surgical exploration/intervention may be required. Put on life support. Monitor life signs, get patient history. Prepare for careful advance to the next stage. 2 - PALLIATIVE CARE & RECOVERY - As patient stabilizes, terminate internal bleeding with rationalized debt, cost control, and a regular diet of stable financing. Rehabilitate. Teach the patient new ways to be productive. Reduce the dependency on Pennsaid. Demonstrate that financial discipline and stable funding can create opportunity: the patient can develop in new directions such as WF10 and Penecure. As patient gains strength, encourage new, healthy relationships with The Street, the media, and investors. Show the patient how to gain trust through transparency, accepting responsibility, and visible commitment. As time passes, new relationships will develop. ~~~~~~~~~~~~~~~~~~~~~~~~~~~ The last few years have had a dangerous effect on perceptions about Dimethaid. The strange failure to raise conventional financing was a cancer which bred cash starvation. That metastasized to inability to finance many things, but especially drug development for Pennsaid, Penecure and WF10. In the case of WF10, insufficient funding was spun as a cost-effective concentration of resources on Pennsaid. It was no such thing. It was the inability to raise enough money. Period. A deadly failure. That failure was further rationalized by minimizing, and, especially online, degrading the potential in WF10. Insufficent funding, insufficent resources, bad perceptions. Even for Pennsaid. In reality they are all very useful products. They need to be developed properly, partnered properly, priced properly, and marketed properly. First aid. Stable, cost-effective financing married to good business practice and coherent development. There's obvious potential. That's my belief. Jim